Search results for "vaccine."

showing 10 items of 789 documents

[Clinical practice and adherence to the diagnosis and treatment of NMIBC guidelines: a report of a recognition based clinical cases study]

2014

For non-muscle invasive bladder cancer, a disease with a considerable epidemiological and socio-economic impact, the introduction of the Guidelines has always evoked as a tool for the resolution of long-standing disputes in terms of diagnosis and therapy. Check the degree of routine clinical practice adherence to the Recommendations is for this disease, more than for other uro-oncology pathology, an urgent need felt by the urological community. To assess the level of Guidelines adherence's, and study issues related to the paths of diagnosis and treatment of non-muscle invasive bladder cancer, and identifying the processes actually implemented in daily clinical practice, a series of case st…

Malemedicine.medical_specialtyPathologyMEDLINEAntineoplastic AgentsDiseaseEpidemiologymedicineHumansRoutine clinical practiceIntensive care medicineNeoplasm StagingBladder cancerbusiness.industryCarcinomaGeneral MedicineEvidence-based medicineMiddle Agedmedicine.diseaseClinical PracticeAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantPractice Guidelines as TopicBCG VaccineGuideline AdherencebusinessStrengths and weaknesses
researchProduct

UNIVERSAL VARICELLA VACCINATION IN THE SICILIAN PAEDIATRIC POPULATION: RAPID UPTAKE OF THE VACCINATION PROGRAMME AND MORBIDITY TRENDS OVER FIVE YEARS

2009

Following the licensure of the Oka/Merck varicella vaccine in Italy in January 2003, the Sicilian health authorities launched a universal vaccination programme in all nine Local Health Units. A two-cohort vaccination strategy was adopted to minimise the shift of the mean age of varicella occurrence to older age groups, with the goal of vaccinating with one dose at least 80% of children in their second year of life and 50% of susceptible adolescents in their 12th year of life. Two studies were implemented in parallel to closely monitor vaccination coverage as well as varicella incidence. Overall, the programme achieved its target, with 87.5% vaccine coverage for the birth cohort 2005 and 90.…

Malemedicine.medical_specialtyPediatricsHerpesvirus 3 HumanVaricella vaccineSettore MED/17 - Malattie InfettiveAdolescentEpidemiologyVaricella vaccinationPediatricsChickenpox VaccineChickenpoxVirologymedicineHumansChildSicilybusiness.industryImmunization ProgramsIncidence (epidemiology)Public healthIncidencePublic Health Environmental and Occupational HealthInfantConfidence intervalVaccinationEl NiñoImmunizationChild PreschoolPopulation SurveillanceFemaleViral diseaseMorbiditybusiness
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

2015

Background: To evaluate the immunological situation against hepatitis B virus (HBV) of a cohort of dentistry students, to analyze the behavior of the levels of hepatitis B surface antigen (anti-HBs) after the administration of one or three vaccine doses, and to determine the influence of age and sex on the immune response. Material and Methods: This retrospective cohort study included students attending the School of Dentistry of the institution where the study was performed from 2005 to 2012 who had completed the public health vaccination calendar for HBV at the age of 12-13. Data on age, sex, basal anti-HBs levels, post-vaccination anti-HBs results and final anti-HBs levels were collected…

Malemedicine.medical_specialtyUniversitieseducationStudents DentalOdontologíamedicine.disease_causeCohort StudiesYoung AdultInternal medicinemedicineHumansHepatitis B VaccinesYoung adultGeneral DentistryRetrospective StudiesHepatitis B virusOral Medicine and PathologyHepatitis B Surface Antigensbiologybusiness.industryResearchRetrospective cohort studyHepatitis B:CIENCIAS MÉDICAS [UNESCO]Hepatitis Bmedicine.diseaseCiencias de la saludVaccinationOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASImmunologyCohortbiology.proteinFemaleSurgeryAntibodybusinessCohort studyMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Oral HPV Infection: Current Strategies for Prevention and Therapy

2012

Infection with High Risk (HR) Human Papillomaviruses (HPVs) is the main aetiological agent of Cervical Squamous Cell Carcinoma (CSCC) and also associated in a subgroup of other neoplasms, including Oropharyngeal Squamous cell Carcinoma (OPSCC). HPV infection, in genital as in oral mucosa, can also be subclinical or associated with benign proliferative lesions (common warts, condylomas, papillomas) caused mostly by infection with Low Risk (LR)-HPVs. In the last decades, extensive research has resulted in growing knowledge on HPV biology and specifically viral life cycle, biochemical properties of viral proteins and their interaction with the host proteins leading to potential new targets of …

Malemedicine.medical_specialtyUterine Cervical NeoplasmsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryEpidemiologyAnimalsHumansMedicineSex organPapillomavirus VaccinesHealth EducationCommon wartsSubclinical infectionPharmacologyta313business.industryTransmission (medicine)Papillomavirus InfectionsHPV infectionvirus diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsVaccinationOropharyngeal NeoplasmsCervical Squamous Cell CarcinomaHigh Risk (HR)HPV infectionDNA ViralImmunologyCarcinoma Squamous CellEtiologyRNA ViralFemaleMouth DiseasesbusinessCurrent Pharmaceutical Design
researchProduct

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of li…

2006

Abstract Background The incidence of local reactions to diphtheria-, tetanus and acellular pertussis (DTaP-) vaccines in infants and toddlers increases with each subsequent dose, and entire thigh swellings (ETS) have been reported. Lowering the amount of antigen or of adjuvant may decrease the reactogenicity of DTaP while maintaining a protective immune response. Objectives Following priming with three doses of a DTaP vaccine during infancy, the safety, reactogenicity and immunogenicity of nine different candidate DTaP-vaccines with reduced amounts of antigen and/or adjuvant given as fourth (booster) dose were evaluated. Methods Study participants were healthy infants aged 15–27 months at t…

Malemedicine.medical_specialtymedicine.medical_treatmentDose-Response Relationship ImmunologicImmunization SecondaryBooster doseDiphtheria-Tetanus-acellular Pertussis VaccinesAdjuvants ImmunologicDouble-Blind MethodAntigenInternal medicineHumansMedicineAntigens BacterialReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer tre…

2015

Objectives To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette–Gu erin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical out…

Malemedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineImmunologicRetrospective Studiehigh gradere-TURHazard ratioMiddle Agedmedicine.anatomical_structureAdministration IntravesicalTreatment Outcome030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortUrinary Bladder NeoplasmBCG VaccineUrologic Surgical Proceduresbladder cancerFemaleHumanReoperationmedicine.medical_specialtyrecurrenceUrologyUrologyT1G3CystectomyArticleCystectomy03 medical and health sciencesbladder cancer; high grade; progression; re-TUR; recurrence; T1G3; UrologyAdjuvants ImmunologicUrethramedicineHumansAdjuvantsT1G3; bladder cancer; high grade; progression; re-TUR; recurrenceRetrospective StudiesAgedNeoplasm StagingBladder cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseSurgerybladder cancer; high grade; progression; re-TUR; recurrence; T1G3; Adjuvants Immunologic; Aged; BCG Vaccine; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Reoperation; Retrospective Studies; Treatment Outcome; Urethra; Urinary Bladder Neoplasms; UrologyUrethraUrinary Bladder NeoplasmsprogressionNeoplasm GradingbusinessBCG vaccine
researchProduct

The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer

2016

BACKGROUND Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomiz…

Malemedicine.medical_treatmentIntravesical drug administration030232 urology & nephrologyKaplan-Meier EstimateBCG ConnaughtSettore MED/24 - Urologia0302 clinical medicineMaintenance therapyMedicine610 Medicine & healthhigh gradeAged 80 and overHazard ratioMiddle AgedAdministration IntravesicalTreatment OutcomeOncology030220 oncology & carcinogenesisCohortbladder cancerFemaleImmunotherapyNon muscle invasivemedicine.medical_specialtyrecurrenceUrologyBCG Connaught; BCG Tice; BCG vaccine; bladder cancer; high grade; Immunotherapy; Intravesical drug administration; progression; recurrence; T1G3; Oncology; UrologyT1G3ArticleMaintenance ChemotherapyBCG Connaught03 medical and health sciencesAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]HumansNeoplasm InvasivenessBCG vaccineAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryImmunotherapy ActiveBCG TiceImmunotherapymedicine.diseaseSurgeryUrinary Bladder NeoplasmsDrug EvaluationprogressionNeoplasm GradingbusinessBCG vaccineFollow-Up StudiesBCG Connaught; BCG Tice; BCG vaccine; Immunotherapy; Intravesical drug administration; T1G3; bladder cancer; high grade; progression; recurrenceUrologic Oncology: Seminars and Original Investigations
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy

2019

Background: Influenza vaccines are updated every year to match the vaccine strains with currently circulating viruses; consequently influenza vaccine effectiveness (IVE) has to be assessed annually.Research design and methods: A test-negative case-control study was conducted within the context of the Italian sentinel influenza surveillance network to estimate IVE by age group, virus subtype, and vaccine brand in medically attended laboratory-confirmed influenza.Results: In Italy, the 2018/19 influenza season was characterized by the co-circulation of influenza A(H1N1)pdm09 and A(H3N2) viruses. The adjusted IVE estimate in preventing influenza was moderate (44.8%, 95% CI: 18.8 to 62.5) again…

Maletest-negative case-control study0301 basic medicinePrevalenceInfluenza vaccine effectiveness test-negative case-control study national influenza surveillance network ItalySettore MED/42 - Igiene Generale E ApplicataInfluenza A Virus H1N1 Subtype0302 clinical medicineDrug DiscoveryEpidemiology030212 general & internal medicineChildInfluenza vaccine effectivenessAged 80 and overnational influenza surveillance networkAge Factorsvirus diseasesMiddle Aged3. Good healthVaccinationTreatment OutcomeItalyInfluenza VaccinesChild PreschoolMolecular MedicineFemaleInfluenza vaccine effectiveness; Italy; national influenza surveillance network; test-negative case-control studyAdultmedicine.medical_specialtyAdolescentInfluenza vaccineImmunologyContext (language use)VirusYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineAnimalsHumansAgedPharmacologybusiness.industryInfluenza A Virus H3N2 SubtypeCase-control studyInfant030104 developmental biologyImmunizationCase-Control StudiesbusinessExpert Review of Vaccines
researchProduct